STAR PipelineDog

STAR-CAD

Canine atopic dermatitis · Caninized anti-IL-31 / IL-13 bispecific

Overview

Species: Dog
Indication: Canine atopic dermatitis
Target: IL-31 / IL-13
Modality: Caninized anti-IL-31 / IL-13 bispecific
Current Stage: Cell Line
Route: Out-licensing at POC

Out-Licensing

Why It Matters

Itch and Inflammation in One Molecule

Canine atopic dermatitis is one of the most common chronic skin diseases in dogs. We are developing a bispecific that blocks the itch pathway (IL-31) and the inflammatory pathway (IL-13) with a single molecule. The programme has been awarded a national R&D grant.

Targets blocked by one molecule

R&D

National grant awarded

Mechanism of action

Bispecific antibody neutralising IL-31 and IL-13 in canine skin — Fig. 1. One bispecific antibody neutralises both IL-31, which drives itch, and IL-13, which drives inflammation. Conceptual; in vivo efficacy is not yet established.

Partnering

Available for Early Out-Licensing

Available for out-licensing once proof of concept is in hand. The full package is shared under a CDA.

Request the Pipeline Package About Partnering

Every programme is in development and pre-approval. Product properties, including dosing interval and efficacy endpoints, are development targets and have not been established in vivo. Technical, market and development detail is available under an executed CDA.